Cigna Healthcare, the health benefits division of the Cigna Group, has released a set of digital tools aimed at improving the ...

Are you looking to keep your blood sugar levels in check and feel fuller for longer? Meet GLP-1, your new best friend in the fight against diabetes and weight management. This powerful hormone is ...

Published across four peer-reviewed journals, this consensus-based guidance reflects an interdisciplinary collaboration to help clinicians support patients receiving GLP-1 receptor agonists for ...

on June 1. Copays, McDonald argued, should be paid after that flu test or STI check are carried out. “This policy is over zealous and disproportionately affects financially vulnerable patients ...

On Thursday, UBS reaffirmed its positive stance on Eli Lilly (NYSE: LLY) shares, maintaining a Buy rating and a price target of $1,050.00.This aligns with the broader Wall Street sentiment, as ...

On Thursday, UBS reaffirmed its positive stance on Eli Lilly (NYSE: LLY) shares, maintaining a Buy rating and a price target of $1,050.00.This aligns with the broader Wall Street sentiment, as ...

Obesity prevalence is rising, with GLP-1 receptor agonists offering promising treatment options, yet access is limited by high costs and insurance restrictions. A study from 2021 to 2024 showed ...

Cleveland Clinic says patients who are unable to pay their copay can set up a 0% interest payment plan to ensure continuity of care. Maddow Blog | Trump directs a new threat at Elon Musk ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes. HealthDay News — For adults with diabetes and obesity, glucagon-like ...

Cigna's leadership in GLP-1 affordability, through initiatives like EncircleRx and the upcoming EnGuide platform, further enhances its positioning. While trailing CVS Health in near-term gains ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...